See the DrugPatentWatch profile for esperoct
Esperoct, also known by its generic name turoctocog alfa, is a recombinant form of coagulation factor VIII used for the treatment of hemophilia A [1].
How does Esperoct work for hemophilia A?
Esperoct is a protein that replaces the deficient factor VIII in individuals with hemophilia A. By providing functional factor VIII, it helps the blood to clot properly, thereby preventing or controlling bleeding episodes [1].
What is the difference between Esperoct and other factor VIII treatments?
Esperoct is a factor VIII product with an extended half-life. This means it stays in the body longer than some conventional factor VIII concentrates. This extended half-life allows for less frequent dosing, which can be a significant benefit for patients in managing their condition [1].
When does the patent for Esperoct expire?
Patent expiry dates are crucial for understanding when generic versions might become available. DrugPatentWatch.com tracks patent information for medications like Esperoct, which can provide insights into future market competition [2]. Specific patent expiry information for Esperoct would need to be consulted through a specialized database like DrugPatentWatch.com.
Who makes Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
What clinical trials have been conducted for Esperoct?
Clinical trials are essential for establishing the safety and efficacy of medications. Studies on Esperoct have focused on its pharmacokinetic profile and its ability to reduce annualized bleeding rates in both adults and children with hemophilia A [1].
What are the potential risks or side effects of Esperoct?
Like other factor VIII products, Esperoct carries risks. These can include allergic reactions, which may manifest as itching, rash, hives, shortness of breath, wheezing, or anaphylaxis. The development of inhibitors (antibodies to factor VIII) is another potential concern, as this can reduce the effectiveness of the treatment. Patients should be monitored for signs of these complications [1].